

Supplementary Figure 1. TM4SF1 promotes HCC progression. (A) Expression of TM4SF1 in GSE32879. (B) Overall survival and progression-free survival analysis based on differential TM4SFS1 expression in TCGA, using the R *survminer* package. (C) Confirmation of TM4SF1 overexpression in MHCC97H and HLF by flow cytometry. (D) 1) CCK-8 assay in MHCC97H and HLF after TM4SF1 overexpression. 2) CCK-8 assay in HepG2 and Huh7 transfected with TM4SF1 overexpression plasmid. (E) Colony formation assay in MHCC97H and HLF following TM4SF1 overexpression. (F) EdU assay in MHCC97H and HLF following TM4SF1 overexpression. (G) Cell-cycle analysis of MHCC97H, HLF and Huh7 following TM4SF1 overexpression. (H) Apoptosis assay of MHCC97H and HLF treated with sorafenib (2 μM) for 48 hours following TM4SF1 overexpression, by flow cytometry. (I) 1) Tumor images and tumor volumes following TM4SF1 overexpression in MHCC97H subcutaneous model (n=5); 2) Representative bioluminescence and tumor images with statistical analysis in orthotopic tumor model (n=5). Data are represented as means±standard deviation. The *P*-values (B) were calculated using log-rank test. The rest of P-values were calculated using the Student's *t*-test (unpaired). **P*<0.05, ***P*<0.01, ****P*<0.001, *****P*<0.0001. TM4SF1, transmembrane 4 L six family member 1; HCC, hepatocellular carcinoma.

 https://doi.org/10.3350/cmh.2024.0934